A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

NCT04236310 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer
ER-positive Breast Cancer

Interventions

DRUG: SHR6390
DRUG: Anastrozole
DRUG: Pyrotinib
DRUG: Trastuzumab

Sponsor

Ruijin Hospital

Collaborators

[object Object]